RxDoctor Payments DataLook up a doctor →

Daragh Heitzman, MD

Neurology · Dallas, TXNPI 1023083961

Payments from drug & device makers

$775,722in general payments, 2019–2025

Across 809 payments — averaging $958.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurology Practice Consortium GPO, LLC$468K
  • Mitsubishi Tanabe Pharma Development America, Inc.$125K
  • Biohaven Pharmaceutical Holding Company Ltd.$43K
  • Orion Corporation$42K
  • UCB SA$36K
  • Amylyx Pharmaceuticals, Inc.$23K
  • plus $39K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Neurology Practice Consortium GPO, LLC7$468,226
Mitsubishi Tanabe Pharma Development America, Inc.8$125,403
Biohaven Pharmaceutical Holding Company Ltd.13$42,524
Orion Corporation9$42,391
UCB SA3$35,605
Amylyx Pharmaceuticals, Inc.47$22,909
Mallinckrodt Enterprises LLC5$13,233
Tanabe Pharma America, Inc.7$10,901
AbbVie(2 entities)100$1,479
Mallinckrodt Hospital Products Inc.1$1,250
Genentech USA, Inc.49$930
UCB, Inc.33$814
Biogen35$711
AstraZeneca31$659
Sunovion Pharmaceuticals Inc.36$581
Teva Pharmaceuticals USA, Inc.30$574
Novartis34$534
Argenx US, Inc.22$516
Pfizer29$474
Lilly USA, LLC25$443
Bristol Myers Squibb22$401
Sanofi10$325
Lundbeck LLC18$322
Eisai Inc.8$318
Neurocrine Biosciences, Inc.12$309
Johnson & Johnson(2 entities)16$305
Merz Pharmaceuticals, LLC10$297
Amgen(2 entities)14$297
Avanir Pharmaceuticals, Inc.33$282
Takeda Pharmaceuticals U.S.A., Inc.12$253
Acadia Pharmaceuticals Inc10$223
Ipsen Biopharmaceuticals, Inc10$208
EMD Serono, Inc.18$187
SK Life Science, Inc.8$170
TG Therapeutics, Inc.8$165
CSL Behring6$134
Amneal Pharmaceuticals LLC7$130
Biohaven Pharmaceuticals, Inc.5$114
Acorda Therapeutics, Inc5$99
Grifols USA, LLC4$80
Catalyst Pharmaceuticals, Inc.4$77
Upsher-smith Laboratories LLC4$68
Avion Pharmaceuticals4$66
Adamas Pharmaceuticals, Inc.3$61
Alnylam Pharmaceuticals Inc.3$61
Harmony Biosciences LLC4$58
EDW Pharma, Inc.1$52
Corium, LLC2$49
Hospira, Inc.3$43
Merz North America, Inc.1$42
Neurelis, Inc.2$39
Boston Scientific2$34
Avadel CNS Pharmaceuticals, LLC2$34
Otsuka America Pharmaceutical, Inc.2$32
GE HealthCare2$30
Tactile Systems Technology Inc1$29
Greenwich Biosciences, Inc.2$28
Kyowa Kirin, Inc.1$27
NS Pharma, Inc.1$23
Axsome Therapeutics, Inc.1$22

How this compares

$775,722 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas →

Medicare billing

Part B allowed, 2024
$1,157,163
Medicare patients
326
Services billed
36,309

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Dallas

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →